Vesicle Epitope Transcript sequencing (VET-seq): Droplet-based Multiomic Profiling Platform for Single Vesicle Analysis

囊泡表位转录本测序 (VET-seq)：用于单囊泡分析的基于液滴的多组学分析平台

基本信息

批准号：
10613257
负责人：
Yue Lu
金额：
$ 24.35万
依托单位：
UNIVERSITY OF UTAH
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-06-01 至 2026-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10613257
关键词：
Address Antibodies Back Bar Codes Benchmarking Biological Biology Blood Blood Cells Cancer Hospital Cancer cell line Cell Culture Techniques Cell model Cells Characteristics Clinical Clinical Oncology Clinical Trials Design Community Clinical Oncology Program Computational Biology Custom Cytolysis DNA Data Detection Development Diagnostic Diameter Disease Drug resistance Encapsulated Epitopes Genetic Health Status High-Throughput Nucleotide Sequencing Human In Situ Individual Investigation Light Malignant Neoplasms Malignant neoplasm of lung Medical Oncologist Membrane Messenger RNA Methods MicroRNAs Microfluidic Microchips Modeling Modification Molecular Moloney Leukemia Virus Monitor Nanotechnology Neoplasm Metastasis Permeability Plasma Play Poly A Poly(A) Tail Polyadenylation Primary Lesion Proteins Proteome Protocols documentation RNA RNA-Directed DNA Polymerase Recurrent Malignant Neoplasm Reporting Resolution Role Sampling Scientist Screening for cancer Serum Signal Transduction Site Source Specimen Stains Surface Systems Biology Technology Therapeutic Tissues Transcript Universities Untranslated RNA Utah Vesicle Work antibody conjugate assay development cancer biomarkers cancer cell cancer drug resistance cancer recurrence combinatorial cost effective detection limit ds-DNA experimental study extracellular vesicles high dimensionality indexing innovation insight liquid biopsy multidisciplinary multiple omics sample fixation single cell analysis statistics trafficking transcriptome transcriptome sequencing treatment response tumor microenvironment

Address Antibodies Back Bar Codes Benchmarking Biological Biology Blood Blood Cells Cancer Hospital Cancer cell line Cell Culture Techniques Cell model Cells Characteristics Clinical Clinical Oncology Clinical Trials Design Community Clinical Oncology Program Computational Biology Custom Cytolysis DNA Data Detection Development Diagnostic Diameter Disease Drug resistance Encapsulated Epitopes Genetic Health Status High-Throughput Nucleotide Sequencing Human In Situ Individual Investigation Light Malignant Neoplasms Malignant neoplasm of lung Medical Oncologist Membrane Messenger RNA Methods MicroRNAs Microfluidic Microchips Modeling Modification Molecular Moloney Leukemia Virus Monitor Nanotechnology Neoplasm Metastasis Permeability Plasma Play Poly A Poly(A) Tail Polyadenylation Primary Lesion Proteins Proteome Protocols documentation RNA RNA-Directed DNA Polymerase Recurrent Malignant Neoplasm Reporting Resolution Role Sampling Scientist Screening for cancer Serum Signal Transduction Site Source Specimen Stains Surface Systems Biology Technology Therapeutic Tissues Transcript Universities Untranslated RNA Utah Vesicle Work antibody conjugate assay development cancer biomarkers cancer cell cancer drug resistance cancer recurrence combinatorial cost effective detection limit ds-DNA experimental study extracellular vesicles high dimensionality indexing innovation insight liquid biopsy multidisciplinary multiple omics sample fixation single cell analysis statistics trafficking transcriptome transcriptome sequencing treatment response tumor microenvironment

展开

项目摘要

ABSTRACT Extracellular vesicles (EVs) are bilayer membrane structures of diameters 30 – 1000 nm released into the blood by cells throughout the body, at concentrations on the order of 1010 per ml. Their molecular content of proteins, dsDNA oligomers, microRNAs (miRNAs), mRNAs, and other analytes, may play multiple functional roles via EV trafficking, and may also provide a diagnostic report back on the disease site or tissue of origin. As such, EVs can serve as potential sources of cancer biomarkers, perhaps even providing insights into the genetic and functional characteristics of the tumor microenvironment. However, this potential remains largely untapped due to technical challenges. We propose to develop an ultra-high-throughput droplet-based multiomic profiling platform, Vesicle Epitope Transcript sequencing (VET-seq), that can simultaneously resolve the surface proteome, internal proteins, and broad RNA spectrum with single extracellular vesicle (sEV) resolution. In AIM 1, we manipulate EVs to permit access to encapsulated EV cargoes and allow in situ modifications of EV molecules. This will yield protocols for detecting a broad spectrum of EV molecules. Here, we also begin to generate and validate custom probes for VET-seq. In AIM 2, we propose an EV indexing approach to add vesicle-specific barcodes to EV molecules that enable the identification of their vesicle-source. This strategy will significantly increase the throughput for droplet-based EV profiling by overcoming the need for limiting dilution. To address the unmet need for a cost-effective multiomic sEV profiling method, in AIM 3, we integrate the in situ modification protocols and the EV indexing protocol to form the VET-seq workflow. We will benchmark the VET-seq protocol on EVs isolated from human cancer cell lines and drug resistance models. The EV detection limit of VET-seq will be determined for cancer-cell derived EVs in a background of EVs isolated from human plasma and serum. High- dimensional sEV profiling enabled by VET-seq will deepen our understanding of the molecular contents and biological implications of EVs in the context of cancer. This will potentially shed light into the utility of EVs as cancer biomarkers for early detection of cancer or recurrent cancer as well as for monitoring treatment response to cancer therapeutics. Our multidisciplinary team is comprised of scientists and clinicians with expertise in micro-nanotechnologies, multiomics analysis, EV biology, computational biology, clinical oncology, and assay development.

抽象的细胞外蔬菜（EV）是直径的双层膜结构30 - 1000 nm释放到血液中通过整个体内的细胞，以每毫升1010的浓度为单位。它们的蛋白质分子含量， DSDNA低聚物，microRNA（miRNA），mRNA和其他分析物可能通过EV发挥多种功能作用贩运，还可以在疾病部位或原产组织中提供诊断报告。因此，电动汽车可以作为癌症生物标志物的潜在来源，甚至可以对遗传和肿瘤微环境的功能特征。但是，这种潜力在很大程度上尚未开发面对技术挑战。我们建议开发一个基于超高通量液滴的多组分分析平台，囊泡表位转录本测序（vet-seq），可以轻松解决表面蛋白，内部蛋白质，并具有单个细胞外囊泡（SEV）分辨率的宽RNA光谱。在AIM 1中，我们操纵电动汽车允许进入封装的EV货物并允许对EV分子进行原位修改。这将产生检测广泛的EV分子的方案。在这里，我们还开始生成和验证自定义 VET-SEQ的问题。在AIM 2中，我们提出了一种EV索引方法，将囊泡特异性条形码添加到EV 能够鉴定其囊泡源的分子。该策略将大大增加基于液滴的EV分析的吞吐量通过克服限制稀释的需求。解决未满足的需要一种具有成本效益的多组分SEV分析方法，在AIM 3中，我们集成了原位修改协议以及形成VET-Seq工作流程的EV索引协议。我们将在电动汽车上基准vet-seq协议从人类癌细胞系和耐药性模型中分离出来。 Vet-Seq的EV检测极限将是在从人血浆和血清分离的电动汽车背景下确定的癌细胞衍生的电动汽车。高的- 兽医seq启用的维度SEV分析将加深我们对分子内容物的理解和电动汽车在癌症背景下的生物学意义。这可能会将电动电动汽车的效用降低到癌症生物标志物早期检测癌症或复发性癌症以及监测治疗反应进行癌症治疗。我们的多学科团队由具有微纳米技术专业知识的科学家和临床医生组成，多组学分析，EV生物学，计算生物学，临床肿瘤学和测定开发。